Biomarkers in melanoma: stage III and IV disease. (Q36050541)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Biomarkers in melanoma: stage III and IV disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Andrzej Slominski

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1

Gerald P Linette

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Martin C Mihm

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Jeffrey S Ross

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

65-74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Biomarkers in melanoma: staging, prognosis and detection of early metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Biomarkers in melanoma: predisposition, screening and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Model predicting survival in stage I melanoma based on tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Individualized prognosis for melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Prognostic significance of allelic losses in primary melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

From polyploidy to aneuploidy, genome instability and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Vaccines for melanoma: translating basic immunology into new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Current developments in cancer vaccines and cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Lack of BRAF mutation in primary uveal melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Absence of exon 15 BRAF germline mutations in familial melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Genomic analysis of metastasis reveals an essential role for RhoC

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

The development of optimal pathological assessment of sentinel lymph nodes for melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Metastasectomy for recurrent stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Prognostic significance of melanoma inhibiting activity levels in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100beta or melanoma inhibitory activity (MIA)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.1.65

21 January 2018

Identifiers

DOI

10.1586/14737159.5.1.65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15723593%20AND%20SRC:MED&resulttype=core&format=json

release_tmsqqn5dtfa4vnohmr2zrka3om

8 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tmsqqn5dtfa4vnohmr2zrka3om

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference